![[U.S. Food and
Drug Administration]](https://webarchive.library.unt.edu/eot2008/20081006134950im_/http://www.fda.gov/icon/header.gif)
IMPORTANT PRESCRIBING NOTICE
Numerous reports have been received by FDA and USP noting confusion between the new product,
Evista (raloxifene HCl), a selective estrogen receptor modulator, marketed by Eli Lilly
for the prevention of osteoporosis in postmenopausal women, and E-Vista, a generic form
of hydroxyzine HCl, formerly manufactured by Seatrace Pharmaceuticals, Inc. (formerly Seatrace
Company). Although E-Vista is no longer manufactured or marketed by Seatrace, reference
to the product still appears in many pharmacy reference texts (e.g., The American Drug Index
, USP, Physicians GENRX, and Facts and Comparisons). Practitioners not
familiar with the new Lilly product have been substituting hydroxyzine HCl for Evista
orders after referring to the above reference texts. New editions of these references will no
longer list E-Vista, but it may take years until the older versions are replaced in
dispensing areas. Please be aware of this very confusing situation, and do not substitute
hydroxyzine HCl for Evista (raloxifene HCl).
###
Return to Summary
![[FDA Home Page]](https://webarchive.library.unt.edu/eot2008/20081006134950im_/http://www.fda.gov/icon/iconhome.gif)